StockNews.AI
ABBV
StockNews.AI
208 days

AbbVie Completes Acquisition of Nimble Therapeutics

1. AbbVie completed its acquisition of Nimble Therapeutics, enhancing its immunology pipeline. 2. Nimble's lead asset targets psoriasis with an investigational oral peptide IL23R inhibitor. 3. AbbVie aims to integrate Nimble's technology for rapid peptide discovery and optimization. 4. The acquisition aligns with AbbVie's commitment to autoimmune disease treatment advancements.

5m saved
Insight
Article

FAQ

Why Bullish?

The acquisition strengthens AbbVie's product pipeline, likely boosting future revenue.

How important is it?

This acquisition expands AbbVie's drug development capabilities, crucial for future growth.

Why Long Term?

The benefits of the acquisition will materialize as new products are developed.

Related Companies

NIMB
NORTH CHICAGO, Ill., Jan. 23, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Nimble Therapeutics. With the completion of the acquisition, Nimble is now a part of AbbVie. Nimble's lead asset is an investigational oral peptide IL23R inhibitor in preclinical development for the treatment of psoriasis. Additionally, Nimble's peptide synthesis, screening, and optimization platform uses proprietary technology to help drive rapid discovery and optimization of oral peptide candidates for a range of targets. "With the acquisition now complete, we are excited to expand our immunology pipeline to include Nimble's novel oral peptide assets and look forward to integrating this proprietary technology into our R&D capabilities," said Jonathon Sedgwick, Ph.D., senior vice president and global head of discovery research, AbbVie. "We are pleased to welcome the talented team at Nimble who share our commitment to elevating the standard of care for people living with autoimmune diseases." For additional background on the acquisition, please read the announcement press release here. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube. Forward-Looking Statements Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2023 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. SOURCE AbbVie

Related News